194 related articles for article (PubMed ID: 38233896)
1. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
Penha FM; Masud M; Khanani ZA; Thomas M; Fong RD; Smith K; Chand A; Khan M; Gahn G; Melo GB; Khanani AM
Int J Retina Vitreous; 2024 Jan; 10(1):5. PubMed ID: 38233896
[TBL] [Abstract][Full Text] [Related]
2. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes.
Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD
Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896
[TBL] [Abstract][Full Text] [Related]
3. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.
Wong TY; Haskova Z; Asik K; Baumal CR; Csaky KG; Eter N; Ives JA; Jaffe GJ; Korobelnik JF; Lin H; Murata T; Ruamviboonsuk P; Schlottmann PG; Seres AI; Silverman D; Sun X; Tang Y; Wells JA; Yoon YH; Wykoff CC;
Ophthalmology; 2024 Jun; 131(6):708-723. PubMed ID: 38158159
[TBL] [Abstract][Full Text] [Related]
4. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale.
Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR
Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184
[TBL] [Abstract][Full Text] [Related]
5. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration.
Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C
Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS; Khanani AM; Quezada Ruiz C; Basu K; Ferrone PJ; Brittain C; Figueroa MS; Lin H; Holz FG; Patel V; Lai TYY; Silverman D; Regillo C; Swaminathan B; Viola F; Cheung CMG; Wong TY;
Lancet; 2022 Feb; 399(10326):729-740. PubMed ID: 35085502
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R;
Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503
[TBL] [Abstract][Full Text] [Related]
8. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM; Kotecha A; Chang A; Chen SJ; Chen Y; Guymer R; Heier JS; Holz FG; Iida T; Ives JA; Lim JI; Lin H; Michels S; Quezada Ruiz C; Schmidt-Erfurth U; Silverman D; Singh R; Swaminathan B; Willis JR; Tadayoni R;
Ophthalmology; 2024 Feb; ():. PubMed ID: 38382813
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M; Kitano S; Ogata N; Mitamura Y; Oh H; Ochi H; Ohsawa S; Hirakata A;
Jpn J Ophthalmol; 2023 May; 67(3):264-279. PubMed ID: 36897413
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA;
Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 2-year results from the Japan subgroup of the phase III TENAYA trial.
Koizumi H; Gomi F; Tsujikawa A; Honda S; Mori R; Ochi H; Iwasaki K; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Mar; ():. PubMed ID: 38483611
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
[TBL] [Abstract][Full Text] [Related]
13. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.
Ferro Desideri L; Traverso CE; Nicolò M; Munk MR
Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242655
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials.
Takahashi K; Cheung CMG; Iida T; Lai TYY; Ohji M; Yanagi Y; Kawano M; Ohsawa S; Suzuki T; Kotecha A; Lin H; Patel V; Swaminathan B; Lee WK;
Graefes Arch Clin Exp Ophthalmol; 2023 Nov; 261(11):3125-3137. PubMed ID: 37294433
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.
Liberski S; Wichrowska M; Kocięcki J
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy, Durability and Safety of Faricimab in the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis.
Watkins C; Paulo T; Bührer C; Holekamp NM; Bagijn M
Adv Ther; 2023 Dec; 40(12):5204-5221. PubMed ID: 37751021
[TBL] [Abstract][Full Text] [Related]
17. [Faricimab: from research to clinical practice].
Yusef YN; Budzinskaya MV; Plyukhova AA
Vestn Oftalmol; 2023; 139(4):115-120. PubMed ID: 37638581
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J; Dugel PU; Patel SS; Chittum ME; Berger B; Del Valle Rubido M; Sadikhov S; Szczesny P; Schwab D; Nogoceke E; Weikert R; Fauser S
JAMA Ophthalmol; 2020 Sep; 138(9):955-963. PubMed ID: 32729888
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, Durability, and Safety of Faricimab in Patients From Asian Countries With Diabetic Macular Edema: 1-Year Subgroup Analysis of the Phase III YOSEMITE and RHINE Trials.
Ishida S; Chen SJ; Murata T; Ogura Y; Ruamviboonsuk P; Sakamoto T; Fujita T; Kawano M; Ohsawa S; Abreu F; Haskova Z; Ives J; Silverman D; Yoon YH;
Asia Pac J Ophthalmol (Phila); 2023 Sep-Oct 01; 12(5):451-459. PubMed ID: 37851562
[TBL] [Abstract][Full Text] [Related]
20. Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Quah NQX; Javed KMAA; Arbi L; Hanumunthadu D
Clin Ophthalmol; 2024; 18():1479-1490. PubMed ID: 38827773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]